Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Tevjf crawled time : 06:00 save search
Open-Angle Glaucoma Therapeutics Market size to grow by USD 2.36 billion from 2022 to 2027, North America to account for 51% of market growth - Technavio
Published: 2023-11-28 (Crawled : 06:00) - prnewswire.com
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.54%
H: 0.08%
C: -0.22%
BHC | $8.6 -0.69% 0.0% 2.1M
|
Health Technology
|
| O: -0.73%
H: 1.17%
C: 0.29%
ALC | $78.47 -0.67% -0.01% 760K
|
Health Technology
|
| O: -0.14%
H: 1.24%
C: 0.53%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
america glaucoma therapeutics growth market
Open-Angle Glaucoma Therapeutics Market to Record a CAGR of 7.18%, Development of Biologics to be a Key Trend - Technavio
Published: 2022-09-27 (Crawled : 06:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: -2.68%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.82%
H: 1.8%
C: -1.4%
TARO | $42.19 -0.12% 0.0% 31K
|
Health Technology
|
| O: -0.1%
H: 1.6%
C: -0.39%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 1.29%
H: 0.42%
C: -1.22%
ALC | $78.47 -0.67% -0.01% 760K
|
Health Technology
|
| O: -0.48%
H: 0.24%
C: -1.13%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.98%
H: 2.07%
C: -0.61%
glaucoma therapeutics market
T-cell lymphoma Market 2026, Growing Geriatric Population to Boost Growth - Technavio
Published: 2022-09-26 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 5.77%
H: 0.0%
C: -2.27%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: -1.15%
H: 0.0%
C: -2.43%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -2.04%
H: 0.82%
C: 0.2%
BAX | News | $39.65 0.33% 0.0% 2.3M
|
Health Technology
|
| O: -0.45%
H: 0.6%
C: -0.45%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.69%
H: 0.51%
C: -0.61%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -2.29%
H: 0.35%
C: -0.67%
BIIB | $190.55 -0.84% -0.84% 1.5M
|
Health Technology
|
| O: -0.17%
H: 1.2%
C: -0.86%
AUTL | $4.8 -0.83% -0.83% 1.2M
|
Health Technology
|
| O: 2.94%
H: 1.43%
C: -0.48%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.52%
H: 0.48%
C: -1.36%
growing t-cell growth market
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
| Email alert
Add to watchlist
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
| Email alert
Add to watchlist
dupixent children
Sciatica Treatment Market Size to Grow by USD 2.52 billion, Rising Awareness about Sciatica to Boost Market Growth - Technavio
Published: 2022-08-22 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 1.54%
H: 1.57%
C: 1.57%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.66%
H: 0.1%
C: -1.43%
TARO | $42.19 -0.12% 0.0% 31K
|
Health Technology
|
| O: 0.78%
H: 0.77%
C: 0.53%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.54%
H: 0.36%
C: -1.07%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: 0.0%
treatment growth market
Chronic Fatigue Syndrome Therapeutics Market Size to Grow by USD 51.84 million, Increasing Use of Off-label Pharmacological Treatment for CFS to Boost Market Growth - Technavio
Published: 2022-08-03 (Crawled : 06:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.21%
H: 0.41%
C: 0.21%
treatment therapeutics growth market
Generic Drugs Market to record USD 138.9 Bn growth -- Technavio identifies North America as a key growth region
Published: 2022-07-27 (Crawled : 06:00) - prnewswire.com
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.1%
H: 1.96%
C: 1.41%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.43%
H: 0.51%
C: 0.32%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.79%
H: 1.44%
C: 1.03%
america growth market
Diffuse Large B-Cell Lymphoma (DLBCL) Therapeutics Market Size to Grow by USD 1.79 billion, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio
Published: 2022-07-25 (Crawled : 06:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.12%
H: 0.06%
C: 0.06%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.06%
H: 0.31%
C: 0.19%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 0.76%
H: 0.19%
C: -1.06%
ADCT | $4.76 -4.03% 0.0% 280K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -2.31%
ABBV | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
CTIC | $9.09 0.05% 11M
|
Health Technology
|
| O: -7.8%
H: 3.72%
C: 2.37%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.37%
H: 0.9%
C: 0.75%
therapeutics market
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Contraceptives Drugs Market Size Will Observe Substantial Growth by 2030 Wilmington, Delaware, United States: Childbearing at an early age has become an issue of concern and to prevent the deaths cause...
Published: 2022-06-23 (Crawled : 06:00) - biospace.com/
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -0.14%
H: 0.14%
C: -2.96%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 1.31%
H: 0.59%
C: 0.54%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
contraceptives growth market
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
Published: 2022-05-31 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.5%
H: 0.54%
C: 0.54%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.21%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -4.05%
dupixent fda review
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
Published: 2022-05-31 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.5%
H: 0.54%
C: 0.54%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -3.21%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -4.05%
dupixent fda review
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Published: 2022-04-07 (Crawled : 06:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -0.61%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.3%
H: 2.79%
C: 2.2%
dupixent children
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Published: 2022-04-04 (Crawled : 06:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.74%
H: 0.6%
C: -0.23%
dupixent fda review order
Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
Published: 2022-04-04 (Crawled : 06:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.74%
H: 0.6%
C: -0.23%
dupixent fda review order
USD 138.90 bn growth in Generic Drugs Market from 2021 to 2025|Technavio
Published: 2021-10-08 (Crawled : 06:00) - prnewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
|
| O: 3.76%
H: 0.0%
C: 0.0%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: 0.44%
H: 1.0%
C: -0.44%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.34%
H: 0.0%
C: 0.0%
drug growth
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.